News Brief: Biosimilar Retacrit Now Available
November 15, 2018
According to news reports, Pfizer has marketed Retacrit (epoetin alfa-epbx), the first biosimilar epoetin alfa (Epogen, Amgen Inc.; Procrit, Janssen Products, LP). The Food and Drug Administration (FDA) approved Retacrit on May 15, 2018.
Retacrit is the sixth biosimilar to be marketed in the United States. It currently is the only biosimilar erythropoiesis-stimulating agent available.
The websites FiercePharma and The Center for Biosimilars both reported the product launch, stating that Retacrit was shipping to wholesalers at a list price of $11.03 per 1,000 units/mL. This represents a 57% discount to Procrit and a 33.5% discount to Epogen.